Clinical Trials
Advancing the Science of Eye Care
MOA serves as a resource for pharmaceutical and medical device companies seeking research partners for FDA and other clinical trials. Participation in these studies offers MOA patients access to additional leading-edge testing and treatment options and, in some cases, the potential to earn compensation.
If you are interested in being considered for current or future studies, contact MOA’s Clinical Research Study Coordinator, Heather Bollinger at hbollinger@moaeyes.com or call 717-219-8769.
Active Enrollment
There are currently no active studies at this time.
There are currently no active studies at this time.
Completed Studies
Demodex TARSUS
This study compares the safety and effectiveness of two different dosing regimens of a treatment for Meibomian Gland Dysfunction in patients with Demodex Blepharitis.
TRINITY Demodex
The study centered around a comprehensive online survey for patients with diagnosed Demodex Blepharitis to learn about different aspects of the patients’ diagnosis, treatment and ongoing care.
Dry Eye Treatment Comparison Study
Effectiveness of TearCare procedures compared to Restasis to treat signs and symptoms of Dry Eye Disease in adult patients.
Dry Eye Flare Questionnaire Study
The Dry Eye Flare Questionnaire is a patient focused questionnaire to learn more about flares, a period of time when dry eye symptoms heighten for a dry eye patient. The study assessed how frequently flares occurred and how patients described their individual symptoms during flares.
TELESCOPE Age-Related Macular Degeneration Trial
A patient identification study primarily designed to identify patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Geographic atrophy is an advanced form of AMD and a leading cause of blindness, without any currently approved therapies.
MIRA–Phase 3 Trial for Mydriasis Medication
Pharmacologically induced mydriasis, a key aspect of ophthalmologic exams and procedures, can lead to photophobia, discomfort and impairment of vision. Depending on the individual and the color of their eyes, the effects of dilation can last anywhere from 6 to over 24 hours. Currently, there are no available options to safely reverse mydriasis. The MIRA-3 study assessed the efficacy of 0.75% phentolamine ophthalmic solution (POS) to reverse pharmacologically induced mydriasis.
Take Part
If you’re interested in taking part in one of our studies, please fill out the contact form and one of our team members will get back to you promptly.